
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.700 | 0.700 | 0.000 |
Stocks | 96.570 | 96.570 | 0.000 |
Other | 2.730 | 2.730 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 13.713 | 14.541 |
Price to Book | 2.466 | 2.067 |
Price to Sales | 1.594 | 1.457 |
Price to Cash Flow | 12.164 | 9.621 |
Dividend Yield | 2.947 | 3.358 |
5 Years Earnings Growth | 14.277 | 9.859 |
Name | Net % | Category Average |
---|---|---|
Financial Services | 23.440 | 19.392 |
Industrials | 22.520 | 16.698 |
Healthcare | 18.150 | 14.422 |
Consumer Cyclical | 8.430 | 9.965 |
Technology | 7.760 | 9.224 |
Communication Services | 6.230 | 5.485 |
Consumer Defensive | 6.060 | 10.705 |
Energy | 2.800 | 4.408 |
Basic Materials | 2.210 | 6.379 |
Utilities | 1.990 | 4.335 |
Real Estate | 0.400 | 1.773 |
Number of long holdings: 77
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 5.85 | 432.0 | -5.45% | |
Schneider Electric | FR0000121972 | 4.09 | 189.50 | -6.65% | |
Deutsche Telekom AG | DE0005557508 | 3.99 | 32.600 | -4.03% | |
AstraZeneca | GB0009895292 | 3.74 | 10,808.0 | -5.13% | |
ABB | CH0012221716 | 3.67 | 41.05 | -4.27% | |
Munich Re Group | DE0008430026 | 3.34 | 559.00 | -5.22% | |
Wolters Kluwer | NL0000395903 | 2.95 | 143.45 | -0.38% | |
BBVA | ES0113211835 | 2.90 | 11.360 | -9.37% | |
Accelleron Industries | CH1169360919 | 2.74 | 36.58 | -5.82% | |
3I Group | GB00B1YW4409 | 2.73 | 3,529.00 | -5.08% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Oddo WerteFonds A | 24.27M | 5.36 | -1.29 | 1.35 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review